Department of Medical Biochemistry and Genetics, and Medicity Research Laboratory, University of Turku, and Turku Graduate School of Biomedical Sciences, Turku, Finland.
Future Oncol. 2010 Jan;6(1):37-53. doi: 10.2217/fon.09.144.
Antibodies targeting the extracellular domains of ErbB receptors have been extensively studied for cancer drug development. This work has led to clinical approval of monoclonal antibodies against the well-known oncogenes EGFR and ErbB2. Here we discuss the biological activities of ErbB4, a less-studied member of the EGFR/ErbB growth factor receptor family and speculate on the potential clinical relevance of antibodies targeting ErbB4. In addition to their significance as therapeutics, the role of ErbB4 antibodies in prognostic and predictive applications is surveyed.
针对 ErbB 受体细胞外结构域的抗体已被广泛研究用于癌症药物开发。这项工作导致了针对著名致癌基因 EGFR 和 ErbB2 的单克隆抗体的临床批准。在这里，我们讨论了 ErbB4 的生物学活性，ErbB4 是 EGFR/ErbB 生长因子受体家族中研究较少的成员，并推测针对 ErbB4 的抗体的潜在临床相关性。除了作为治疗剂的重要性外，还调查了 ErbB4 抗体在预后和预测应用中的作用。
